Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1
Identifieur interne : 000401 ( Istex/Corpus ); précédent : 000400; suivant : 000402Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1
Auteurs : A. Ebersold ; V. Boyer ; P. J. Klasse ; M. Holnigue ; C. Fraisier ; J. M. Cocchi ; R. Pipkorn ; J. Blomberg ; C. DesgrangesSource :
- Research in Virology [ 0923-2516 ] ; 1992.
English descriptors
- KwdEn :
- Teeft :
- Agence nationale, Assay, Biological activities, Colorimetric assay, Culture supernatants, Cytofluorimetric analysis, Elisa, Envelope glycoprotein, Epitope, Glycoprotein, Highest concentration, Hiv1, Hiv1 infection, Hivi, Hmab, Human immunodeficiency virus, Human immunodeficiency virus type, Hybrid growth, Immunization, Immunodeficiency, Immunosuppressive, Immunosuppressive effect, Klasse, Light chains, Lymphocyte, Mmab, Molt4 cells, Monoclonal antibody, Monoclonal humain, Negative control, Neutralization, Neutralization assays, Neutralizing, Neutralizing antibodies, Pbmc, Peptide, Peripheral blood, Phivis, Proliferation assay, Room temperature, Same region, Simian immunodeficiency virus, Single residues, Spleen, Spleen cells, Supernatant, Supt1 target cells, Supti target cells, Syncytia formation, Syncytium, Synthetic peptide, Target cells, Transmembrane protein, Uninfected supt1 target cells, Virol.
Abstract
Summary: Human spleen cells from an HIV-seropositive donor were immunized in vitro with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.
Les lymphocytes de la rate d'un donneur séropositif pour le VIH ont été immunisés in vitro par un peptide synthétique constitué des acides aminés 583 à 599 de la région immunosuppressive de la gp41 du VIH. Pour l'immunisation, le peptide a été couplé à un «noyau heptalysine portant huit extrémités NH2-réactives. Ce même peptide a été injecté en parallèle à des souris. Un anticorps monoclonal humain et un anticorps monoclonal murin ont été obtenus. Tous deux d'isotype IgM, ils présentent une réactivité différente sur un groupe de 42 peptides présentant des modifications de séquence. Les deux anticorps n'inhibent pas les propriétés immunosuppressives du peptide 583–599 et ne neutralisent ni n'augmentent l'infection par du virus libre. Toutefois, l'anticorps monoclonal humain, et lui seul, présente la capacité d'inhiber la formation de syncytia entre des cellules infectées par différentes souches du VIH1 et des cellules cibles, cela à une concentration de 20 μg/ml. Le haut degré de conservation des acides aminés dans la région 583–599 fait de l'anticorps monoclonal humain un candidat éventuel pour des études d'immunothérapie passive.
Url:
DOI: 10.1016/S0923-2516(06)80102-0
Links to Exploration step
ISTEX:D485D531AA1B2F6D22431C4A22EFCE818A012DEFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title><author><name sortKey="Ebersold, A" sort="Ebersold, A" uniqKey="Ebersold A" first="A." last="Ebersold">A. Ebersold</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation><affiliation><mods:affiliation>Corresponding author.</mods:affiliation></affiliation></author><author><name sortKey="Boyer, V" sort="Boyer, V" uniqKey="Boyer V" first="V." last="Boyer">V. Boyer</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Klasse, P J" sort="Klasse, P J" uniqKey="Klasse P" first="P. J." last="Klasse">P. J. Klasse</name><affiliation><mods:affiliation>Section of Virology, Lund University, Lund (Sweden)</mods:affiliation></affiliation></author><author><name sortKey="Holnigue, M" sort="Holnigue, M" uniqKey="Holnigue M" first="M." last="Holnigue">M. Holnigue</name><affiliation><mods:affiliation>Centre Régional de Transfusion sanguine, 59000 Lille (France)</mods:affiliation></affiliation></author><author><name sortKey="Fraisier, C" sort="Fraisier, C" uniqKey="Fraisier C" first="C." last="Fraisier">C. Fraisier</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Cocchi, J M" sort="Cocchi, J M" uniqKey="Cocchi J" first="J. M." last="Cocchi">J. M. Cocchi</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Pipkorn, R" sort="Pipkorn, R" uniqKey="Pipkorn R" first="R." last="Pipkorn">R. Pipkorn</name><affiliation><mods:affiliation>Novabiochem AG, Sandhausen, Heidelberg (Germany)</mods:affiliation></affiliation></author><author><name sortKey="Blomberg, J" sort="Blomberg, J" uniqKey="Blomberg J" first="J." last="Blomberg">J. Blomberg</name><affiliation><mods:affiliation>Section of Virology, Lund University, Lund (Sweden)</mods:affiliation></affiliation></author><author><name sortKey="Desgranges, C" sort="Desgranges, C" uniqKey="Desgranges C" first="C." last="Desgranges">C. Desgranges</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D485D531AA1B2F6D22431C4A22EFCE818A012DEF</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/S0923-2516(06)80102-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000401</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000401</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title><author><name sortKey="Ebersold, A" sort="Ebersold, A" uniqKey="Ebersold A" first="A." last="Ebersold">A. Ebersold</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation><affiliation><mods:affiliation>Corresponding author.</mods:affiliation></affiliation></author><author><name sortKey="Boyer, V" sort="Boyer, V" uniqKey="Boyer V" first="V." last="Boyer">V. Boyer</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Klasse, P J" sort="Klasse, P J" uniqKey="Klasse P" first="P. J." last="Klasse">P. J. Klasse</name><affiliation><mods:affiliation>Section of Virology, Lund University, Lund (Sweden)</mods:affiliation></affiliation></author><author><name sortKey="Holnigue, M" sort="Holnigue, M" uniqKey="Holnigue M" first="M." last="Holnigue">M. Holnigue</name><affiliation><mods:affiliation>Centre Régional de Transfusion sanguine, 59000 Lille (France)</mods:affiliation></affiliation></author><author><name sortKey="Fraisier, C" sort="Fraisier, C" uniqKey="Fraisier C" first="C." last="Fraisier">C. Fraisier</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Cocchi, J M" sort="Cocchi, J M" uniqKey="Cocchi J" first="J. M." last="Cocchi">J. M. Cocchi</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author><author><name sortKey="Pipkorn, R" sort="Pipkorn, R" uniqKey="Pipkorn R" first="R." last="Pipkorn">R. Pipkorn</name><affiliation><mods:affiliation>Novabiochem AG, Sandhausen, Heidelberg (Germany)</mods:affiliation></affiliation></author><author><name sortKey="Blomberg, J" sort="Blomberg, J" uniqKey="Blomberg J" first="J." last="Blomberg">J. Blomberg</name><affiliation><mods:affiliation>Section of Virology, Lund University, Lund (Sweden)</mods:affiliation></affiliation></author><author><name sortKey="Desgranges, C" sort="Desgranges, C" uniqKey="Desgranges C" first="C." last="Desgranges">C. Desgranges</name><affiliation><mods:affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Research in Virology</title><title level="j" type="abbrev">X135</title><idno type="ISSN">0923-2516</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">143</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="179">179</biblScope><biblScope unit="page" to="191">191</biblScope></imprint><idno type="ISSN">0923-2516</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-2516</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Lymphocyte, Peptide, HIV, AIDS, mAb, IgM, Immunotherapy</term><term>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Agence nationale</term><term>Assay</term><term>Biological activities</term><term>Colorimetric assay</term><term>Culture supernatants</term><term>Cytofluorimetric analysis</term><term>Elisa</term><term>Envelope glycoprotein</term><term>Epitope</term><term>Glycoprotein</term><term>Highest concentration</term><term>Hiv1</term><term>Hiv1 infection</term><term>Hivi</term><term>Hmab</term><term>Human immunodeficiency virus</term><term>Human immunodeficiency virus type</term><term>Hybrid growth</term><term>Immunization</term><term>Immunodeficiency</term><term>Immunosuppressive</term><term>Immunosuppressive effect</term><term>Klasse</term><term>Light chains</term><term>Lymphocyte</term><term>Mmab</term><term>Molt4 cells</term><term>Monoclonal antibody</term><term>Monoclonal humain</term><term>Negative control</term><term>Neutralization</term><term>Neutralization assays</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Pbmc</term><term>Peptide</term><term>Peripheral blood</term><term>Phivis</term><term>Proliferation assay</term><term>Room temperature</term><term>Same region</term><term>Simian immunodeficiency virus</term><term>Single residues</term><term>Spleen</term><term>Spleen cells</term><term>Supernatant</term><term>Supt1 target cells</term><term>Supti target cells</term><term>Syncytia formation</term><term>Syncytium</term><term>Synthetic peptide</term><term>Target cells</term><term>Transmembrane protein</term><term>Uninfected supt1 target cells</term><term>Virol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Human spleen cells from an HIV-seropositive donor were immunized in vitro with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.</div><div type="abstract" xml:lang="fr">Les lymphocytes de la rate d'un donneur séropositif pour le VIH ont été immunisés in vitro par un peptide synthétique constitué des acides aminés 583 à 599 de la région immunosuppressive de la gp41 du VIH. Pour l'immunisation, le peptide a été couplé à un «noyau heptalysine portant huit extrémités NH2-réactives. Ce même peptide a été injecté en parallèle à des souris. Un anticorps monoclonal humain et un anticorps monoclonal murin ont été obtenus. Tous deux d'isotype IgM, ils présentent une réactivité différente sur un groupe de 42 peptides présentant des modifications de séquence. Les deux anticorps n'inhibent pas les propriétés immunosuppressives du peptide 583–599 et ne neutralisent ni n'augmentent l'infection par du virus libre. Toutefois, l'anticorps monoclonal humain, et lui seul, présente la capacité d'inhiber la formation de syncytia entre des cellules infectées par différentes souches du VIH1 et des cellules cibles, cela à une concentration de 20 μg/ml. Le haut degré de conservation des acides aminés dans la région 583–599 fait de l'anticorps monoclonal humain un candidat éventuel pour des études d'immunothérapie passive.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>peptide</json:string><json:string>hmab</json:string><json:string>epitope</json:string><json:string>syncytium</json:string><json:string>hiv1</json:string><json:string>immunodeficiency</json:string><json:string>mmab</json:string><json:string>neutralizing</json:string><json:string>assay</json:string><json:string>lymphocyte</json:string><json:string>klasse</json:string><json:string>syncytia formation</json:string><json:string>hivi</json:string><json:string>immunosuppressive</json:string><json:string>elisa</json:string><json:string>phivis</json:string><json:string>glycoprotein</json:string><json:string>virol</json:string><json:string>negative control</json:string><json:string>pbmc</json:string><json:string>human immunodeficiency virus type</json:string><json:string>target cells</json:string><json:string>spleen cells</json:string><json:string>immunization</json:string><json:string>supernatant</json:string><json:string>synthetic peptide</json:string><json:string>immunosuppressive effect</json:string><json:string>human immunodeficiency virus</json:string><json:string>single residues</json:string><json:string>neutralization</json:string><json:string>hiv1 infection</json:string><json:string>culture supernatants</json:string><json:string>room temperature</json:string><json:string>spleen</json:string><json:string>uninfected supt1 target cells</json:string><json:string>highest concentration</json:string><json:string>peripheral blood</json:string><json:string>light chains</json:string><json:string>neutralization assays</json:string><json:string>molt4 cells</json:string><json:string>colorimetric assay</json:string><json:string>monoclonal antibody</json:string><json:string>hybrid growth</json:string><json:string>agence nationale</json:string><json:string>cytofluorimetric analysis</json:string><json:string>supt1 target cells</json:string><json:string>supti target cells</json:string><json:string>biological activities</json:string><json:string>monoclonal humain</json:string><json:string>same region</json:string><json:string>transmembrane protein</json:string><json:string>simian immunodeficiency virus</json:string><json:string>proliferation assay</json:string><json:string>envelope glycoprotein</json:string><json:string>neutralizing antibodies</json:string></teeft></keywords><subject><json:item><lang><json:string>eng</json:string></lang><value>Lymphocyte, Peptide, HIV, AIDS, mAb, IgM, Immunotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Lymphocyte, HIV, Peptide, Anticorps monoclonal, IgM, VIH1, SIDA, Immunothérapie</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><qualityIndicators><score>8.884</score><pdfWordCount>5694</pdfWordCount><pdfCharCount>33760</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>13</pdfPageCount><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>157</abstractWordCount><abstractCharCount>1098</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title><pii><json:string>S0923-2516(06)80102-0</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Research in Virology</title><language><json:string>unknown</json:string></language><publicationDate>1992</publicationDate><issn><json:string>0923-2516</json:string></issn><pii><json:string>S0923-2516(06)X8065-2</json:string></pii><volume>143</volume><pages><first>179</first><last>191</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1992</json:string></date><geogName></geogName><orgName><json:string>Novabiochem</json:string><json:string>Wellcome Diagnostics, Dartford, England</json:string><json:string>Institut National</json:string></orgName><orgName_funder><json:string>Institut National</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Albert Thomas</json:string><json:string>A. Ebersold</json:string><json:string>G.J. Demond</json:string><json:string>R. Pipkorn</json:string><json:string>H. Broly</json:string><json:string>La Coquette</json:string><json:string>Western</json:string><json:string>J.M. Huart</json:string><json:string>Mouton</json:string><json:string>M. Holnigue</json:string></persName><placeName><json:string>TX</json:string><json:string>Uppsala</json:string><json:string>Paris</json:string><json:string>Germany</json:string><json:string>Heidelberg</json:string><json:string>USA</json:string><json:string>Strasbourg</json:string><json:string>CA</json:string><json:string>France</json:string><json:string>Marseille</json:string><json:string>Kallestad</json:string><json:string>Sweden</json:string><json:string>Lille</json:string><json:string>Mountain View</json:string><json:string>Lyon</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Cheingsong-Popov et al., 1990</json:string><json:string>Trabaud et al., 1989</json:string><json:string>Weiss et al., 1985</json:string><json:string>Shafferman et aL, 1991</json:string><json:string>Skinner et al., 1988a</json:string><json:string>Ruegg et al. (1989)</json:string><json:string>Dalgleish et al., 1988</json:string><json:string>Qureshi et al. (1990)</json:string><json:string>Matsushita et al., 1988</json:string><json:string>Durda et al., 1990</json:string><json:string>Ho et aL, 1987</json:string><json:string>Cianciolo et al., 1988</json:string><json:string>Matthews et al.</json:string><json:string>Klasse et al., 1988</json:string><json:string>Nara et al., 1987</json:string><json:string>Qureshi et al., 1990</json:string><json:string>Reitz et al., 1988</json:string><json:string>Cordell et al., 1991</json:string><json:string>Wilson et ak, 1990</json:string><json:string>Modrow et al., 1987</json:string><json:string>Celada et al., 1990</json:string><json:string>Scott et al., 1990</json:string><json:string>Lange et al., 1989</json:string><json:string>Boyer et al., 1991</json:string><json:string>RobertGuroff et al., 1985</json:string><json:string>Robertson et al., 1988</json:string><json:string>Skinner et al., 1988b</json:string><json:string>Borrebaeck et al., 1988</json:string><json:string>Robinson et al. (1990)</json:string><json:string>Shafferman et al. (1991)</json:string><json:string>Ruegg et aL, 1989</json:string><json:string>Robinson et al., 1989</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-03DRLF6T-T</json:string></ark><categories><wos></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie infectieuse</json:string></inist></categories><publicationDate>1992</publicationDate><author><json:item><name>A. Ebersold</name><affiliations><json:string>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</json:string><json:string>Corresponding author.</json:string></affiliations></json:item><json:item><name>V. Boyer</name><affiliations><json:string>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</json:string></affiliations></json:item><json:item><name>P.J. Klasse</name><affiliations><json:string>Section of Virology, Lund University, Lund (Sweden)</json:string></affiliations></json:item><json:item><name>M. Holnigue</name><affiliations><json:string>Centre Régional de Transfusion sanguine, 59000 Lille (France)</json:string></affiliations></json:item><json:item><name>C. Fraisier</name><affiliations><json:string>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</json:string></affiliations></json:item><json:item><name>J.M. Cocchi</name><affiliations><json:string>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</json:string></affiliations></json:item><json:item><name>R. Pipkorn</name><affiliations><json:string>Novabiochem AG, Sandhausen, Heidelberg (Germany)</json:string></affiliations></json:item><json:item><name>J. Blomberg</name><affiliations><json:string>Section of Virology, Lund University, Lund (Sweden)</json:string></affiliations></json:item><json:item><name>C. Desgranges</name><affiliations><json:string>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</json:string></affiliations></json:item></author><articleId><json:string>80102</json:string></articleId><arkIstex>ark:/67375/6H6-03DRLF6T-T</arkIstex><abstract>Summary: Human spleen cells from an HIV-seropositive donor were immunized in vitro with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.</abstract><pmid><json:string>1381515</json:string></pmid><serie><title>Proc. nat. Acad. Sci. (Wash.)</title><language><json:string>unknown</json:string></language><volume>85</volume><pages><first>3995</first></pages></serie><copyrightDate>1992</copyrightDate><doi><json:string>10.1016/S0923-2516(06)80102-0</json:string></doi><id>D485D531AA1B2F6D22431C4A22EFCE818A012DEF</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title><title level="a" type="alt" xml:lang="fr">Anticorps monoclonaux humain et murin dirigés contre une séquence conservée de la gp41 (aa583-599) du virus de l'immunodéficience humaine</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>©1992 Éditions Scientifiques Elsevier, Paris</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</p></availability><date>1992</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title><title level="a" type="alt" xml:lang="fr">Anticorps monoclonaux humain et murin dirigés contre une séquence conservée de la gp41 (aa583-599) du virus de l'immunodéficience humaine</title><author xml:id="author-0000"><persName><forename type="first">A.</forename><surname>Ebersold</surname></persName><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><affiliation>Corresponding author.</affiliation></author><author xml:id="author-0001"><persName><forename type="first">V.</forename><surname>Boyer</surname></persName><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation></author><author xml:id="author-0002"><persName><forename type="first">P.J.</forename><surname>Klasse</surname></persName><affiliation>Section of Virology, Lund University, Lund (Sweden)</affiliation></author><author xml:id="author-0003"><persName><forename type="first">M.</forename><surname>Holnigue</surname></persName><affiliation>Centre Régional de Transfusion sanguine, 59000 Lille (France)</affiliation></author><author xml:id="author-0004"><persName><forename type="first">C.</forename><surname>Fraisier</surname></persName><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation></author><author xml:id="author-0005"><persName><forename type="first">J.M.</forename><surname>Cocchi</surname></persName><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation></author><author xml:id="author-0006"><persName><forename type="first">R.</forename><surname>Pipkorn</surname></persName><affiliation>Novabiochem AG, Sandhausen, Heidelberg (Germany)</affiliation></author><author xml:id="author-0007"><persName><forename type="first">J.</forename><surname>Blomberg</surname></persName><affiliation>Section of Virology, Lund University, Lund (Sweden)</affiliation></author><author xml:id="author-0008"><persName><forename type="first">C.</forename><surname>Desgranges</surname></persName><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation></author><idno type="istex">D485D531AA1B2F6D22431C4A22EFCE818A012DEF</idno><idno type="ark">ark:/67375/6H6-03DRLF6T-T</idno><idno type="DOI">10.1016/S0923-2516(06)80102-0</idno><idno type="PII">S0923-2516(06)80102-0</idno><idno type="article-id">80102</idno></analytic><monogr><title level="j">Research in Virology</title><title level="j" type="abbrev">X135</title><idno type="pISSN">0923-2516</idno><idno type="PII">S0923-2516(06)X8065-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992"></date><biblScope unit="volume">143</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="179">179</biblScope><biblScope unit="page" to="191">191</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Human spleen cells from an HIV-seropositive donor were immunized in vitro with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.</p></abstract><abstract xml:lang="fr"><p>Les lymphocytes de la rate d'un donneur séropositif pour le VIH ont été immunisés in vitro par un peptide synthétique constitué des acides aminés 583 à 599 de la région immunosuppressive de la gp41 du VIH. Pour l'immunisation, le peptide a été couplé à un «noyau heptalysine portant huit extrémités NH2-réactives. Ce même peptide a été injecté en parallèle à des souris. Un anticorps monoclonal humain et un anticorps monoclonal murin ont été obtenus. Tous deux d'isotype IgM, ils présentent une réactivité différente sur un groupe de 42 peptides présentant des modifications de séquence. Les deux anticorps n'inhibent pas les propriétés immunosuppressives du peptide 583–599 et ne neutralisent ni n'augmentent l'infection par du virus libre. Toutefois, l'anticorps monoclonal humain, et lui seul, présente la capacité d'inhiber la formation de syncytia entre des cellules infectées par différentes souches du VIH1 et des cellules cibles, cela à une concentration de 20 μg/ml. Le haut degré de conservation des acides aminés dans la région 583–599 fait de l'anticorps monoclonal humain un candidat éventuel pour des études d'immunothérapie passive.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Key-words</head><item><term>Lymphocyte, Peptide, HIV, AIDS, mAb, IgM, Immunotherapy</term></item><item><term>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</term></item></list></keywords></textClass><textClass xml:lang="fr"><keywords scheme="keyword"><list><head>Mots-clés</head><item><term>Lymphocyte, HIV, Peptide, Anticorps monoclonal, IgM, VIH1, SIDA, Immunothérapie</term></item><item><term>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><article version="5.0" xml:lang="en" docsubtype="fla"><item-info><jid>X135</jid><aid>80102</aid><ce:pii>S0923-2516(06)80102-0</ce:pii><ce:doi>10.1016/S0923-2516(06)80102-0</ce:doi><ce:copyright type="unknown" year="1992">Éditions Scientifiques Elsevier, Paris</ce:copyright></item-info><head><ce:title>Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</ce:title><ce:alt-title xml:lang="fr">Anticorps monoclonaux humain et murin dirigés contre une séquence conservée de la gp41 (aa583-599) du virus de l'immunodéficience humaine</ce:alt-title><ce:author-group><ce:author><ce:given-name>A.</ce:given-name><ce:surname>Ebersold</ce:surname><ce:cross-ref refid="aff1"><ce:sup>(1)</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>(*)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>V.</ce:given-name><ce:surname>Boyer</ce:surname><ce:cross-ref refid="aff1"><ce:sup>(1)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>P.J.</ce:given-name><ce:surname>Klasse</ce:surname><ce:cross-ref refid="aff2"><ce:sup>(2)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.</ce:given-name><ce:surname>Holnigue</ce:surname><ce:cross-ref refid="aff3"><ce:sup>(3)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>C.</ce:given-name><ce:surname>Fraisier</ce:surname><ce:cross-ref refid="aff1"><ce:sup>(1)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>J.M.</ce:given-name><ce:surname>Cocchi</ce:surname><ce:cross-ref refid="aff1"><ce:sup>(1)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>R.</ce:given-name><ce:surname>Pipkorn</ce:surname><ce:cross-ref refid="aff4"><ce:sup>(4)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>J.</ce:given-name><ce:surname>Blomberg</ce:surname><ce:cross-ref refid="aff2"><ce:sup>(2)</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>C.</ce:given-name><ce:surname>Desgranges</ce:surname><ce:cross-ref refid="aff1"><ce:sup>(1)</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>(1)</ce:label><ce:textfn>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>(2)</ce:label><ce:textfn>Section of Virology, Lund University, Lund (Sweden)</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>(3)</ce:label><ce:textfn>Centre Régional de Transfusion sanguine, 59000 Lille (France)</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>(4)</ce:label><ce:textfn>Novabiochem AG, Sandhausen, Heidelberg (Germany)</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>(*)</ce:label><ce:text>Corresponding author.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="5" month="2" year="1992"></ce:date-received><ce:date-accepted day="24" month="4" year="1992"></ce:date-accepted><ce:abstract id="ab1" class="author" xml:lang="en"><ce:section-title>Summary</ce:section-title><ce:abstract-sec><ce:simple-para>Human spleen cells from an HIV-seropositive donor were immunized <ce:italic>in vitro</ce:italic> with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract id="ab2" class="author" xml:lang="fr"><ce:abstract-sec><ce:simple-para>Les lymphocytes de la rate d'un donneur séropositif pour le VIH ont été immunisés <ce:italic>in vitro</ce:italic> par un peptide synthétique constitué des acides aminés 583 à 599 de la région immunosuppressive de la gp41 du VIH. Pour l'immunisation, le peptide a été couplé à un «noyau heptalysine portant huit extrémités NH<ce:inf loc="post">2</ce:inf>-réactives. Ce même peptide a été injecté en parallèle à des souris. Un anticorps monoclonal humain et un anticorps monoclonal murin ont été obtenus. Tous deux d'isotype IgM, ils présentent une réactivité différente sur un groupe de 42 peptides présentant des modifications de séquence. Les deux anticorps n'inhibent pas les propriétés immunosuppressives du peptide 583–599 et ne neutralisent ni n'augmentent l'infection par du virus libre. Toutefois, l'anticorps monoclonal humain, et lui seul, présente la capacité d'inhiber la formation de syncytia entre des cellules infectées par différentes souches du VIH1 et des cellules cibles, cela à une concentration de 20 μg/ml. Le haut degré de conservation des acides aminés dans la région 583–599 fait de l'anticorps monoclonal humain un candidat éventuel pour des études d'immunothérapie passive.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword" xml:lang="en"><ce:section-title>Key-words</ce:section-title><ce:keyword><ce:text>Lymphocyte, Peptide, HIV, AIDS, mAb, IgM, Immunotherapy</ce:text></ce:keyword><ce:keyword><ce:text>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</ce:text></ce:keyword></ce:keywords><ce:keywords class="keyword" xml:lang="fr"><ce:section-title>Mots-clés</ce:section-title><ce:keyword><ce:text>Lymphocyte, HIV, Peptide, Anticorps monoclonal, IgM, VIH1, SIDA, Immunothérapie</ce:text></ce:keyword><ce:keyword><ce:text>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</ce:text></ce:keyword></ce:keywords></head><tail><ce:bibliography><ce:section-title>References</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>Borrebaeck, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Borrebaeck</ce:surname><ce:given-name>C.A.K.</ce:given-name></sb:author><sb:author><ce:surname>Danielsson</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Möller</ce:surname><ce:given-name>S.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Human monoclonal antibodies produced by primary <ce:italic>in vitro</ce:italic> immunization of peripheral blood lymphocytes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. nat. Acad. Sci. (Wash.)</sb:maintitle></sb:title><sb:volume-nr>85</sb:volume-nr></sb:series></sb:book-series><sb:date>1988</sb:date></sb:edited-book><sb:pages><sb:first-page>3995</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Boyer, et al, 1991</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Boyer</ce:surname><ce:given-name>V.</ce:given-name></sb:author><sb:author><ce:surname>Broly</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Souche</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Madaule</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Rossier</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Zagury</ce:surname><ce:given-name>D.</ce:given-name></sb:author><sb:author><ce:surname>Desgranges</ce:surname><ce:given-name>C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Characterization and large production of human monoclonal antibodies against the HIV-1 envelope</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. exp. Immunol.</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>452</sb:first-page><sb:last-page>459</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>Celada, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Celada</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Cambiaggi</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Maccari</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Burastero</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Gregory</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:author><ce:surname>Patzer</ce:surname><ce:given-name>E.</ce:given-name></sb:author><sb:author><ce:surname>Porter</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>McDanal</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Matthews</ce:surname><ce:given-name>T.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. exp. Med.</sb:maintitle></sb:title><sb:volume-nr>172</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>1143</sb:first-page><sb:last-page>1150</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>Cheingsong-Popov, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cheingsong-Popov</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Panagiotidi</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Caun</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Klasse</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Pipkorn</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Blomberg</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Weber</ce:surname><ce:given-name>J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583–599), do not correlate significantly with outcome in HIV infection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>251</sb:first-page><sb:last-page>253</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>Cianciolo, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cianciolo</ce:surname><ce:given-name>G.J.</ce:given-name></sb:author><sb:author><ce:surname>Bogerd</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Snyderman</ce:surname><ce:given-name>R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Immunol. Letters</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>7</sb:first-page><sb:last-page>14</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>Cordell, et al, 1991</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cordell</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Moore</ce:surname><ce:given-name>J.P.</ce:given-name></sb:author><sb:author><ce:surname>Dean</ce:surname><ce:given-name>C.J.</ce:given-name></sb:author><sb:author><ce:surname>Klasse</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:author><ce:surname>Weiss</ce:surname><ce:given-name>R.A.</ce:given-name></sb:author><sb:author><ce:surname>McKeating</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding <ce:italic>in vitro</ce:italic></sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Virology</sb:maintitle></sb:title><sb:volume-nr>185</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>72</sb:first-page><sb:last-page>79</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>Dalgleish, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Dalgleish</ce:surname><ce:given-name>A.G.</ce:given-name></sb:author><sb:author><ce:surname>Chanh</ce:surname><ce:given-name>T.C.</ce:given-name></sb:author><sb:author><ce:surname>Kennedy</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author><sb:author><ce:surname>Kanda</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Clapham</ce:surname><ce:given-name>P.R.</ce:given-name></sb:author><sb:author><ce:surname>Weiss</ce:surname><ce:given-name>R.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Virology</sb:maintitle></sb:title><sb:volume-nr>165</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>209</sb:first-page><sb:last-page>215</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>Döpel, et al, 1989</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Döpel</ce:surname><ce:given-name>S.-H.</ce:given-name></sb:author><sb:author><ce:surname>Porstmann</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:author><ce:surname>Henklein</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Von Baehr</ce:surname><ce:given-name>R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Fine mapping of an immunodominant region of the transmembrane protein of the human immunodeficiency virus (HIV-1)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. virol. Methods</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>167</sb:first-page><sb:last-page>178</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>Durda, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Durda</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:author><ce:surname>Bacheler</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Clapham</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Jenoski</ce:surname><ce:given-name>A.M.</ce:given-name></sb:author><sb:author><ce:surname>Leece</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Matthews</ce:surname><ce:given-name>T.J.</ce:given-name></sb:author><sb:author><ce:surname>McKnight</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Pomerantz</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Rayner</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Weinhold</ce:surname><ce:given-name>K.J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS Res. Hum. Retrovirus</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>1115</sb:first-page><sb:last-page>1123</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>Hammond, et al, 1991</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hammond</ce:surname><ce:given-name>S.A.</ce:given-name></sb:author><sb:author><ce:surname>Obah</ce:surname><ce:given-name>E.</ce:given-name></sb:author><sb:author><ce:surname>Stanhope</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:author><ce:surname>Monell</ce:surname><ce:given-name>C.R.</ce:given-name></sb:author><sb:author><ce:surname>Strand</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Robbins</ce:surname><ce:given-name>F.M.</ce:given-name></sb:author><sb:author><ce:surname>Bias</ce:surname><ce:given-name>W.B.</ce:given-name></sb:author><sb:author><ce:surname>Karr</ce:surname><ce:given-name>R.W.</ce:given-name></sb:author><sb:author><ce:surname>Koenig</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Siliciano</ce:surname><ce:given-name>R.F.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Characterization of a conserved T-cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Immunol.</sb:maintitle></sb:title><sb:volume-nr>146</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>1470</sb:first-page><sb:last-page>1477</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>Ho, et al, 1987</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ho</ce:surname><ce:given-name>D.D.</ce:given-name></sb:author><sb:author><ce:surname>Sarngadharan</ce:surname><ce:given-name>M.G.</ce:given-name></sb:author><sb:author><ce:surname>Hirsh</ce:surname><ce:given-name>M.S.</ce:given-name></sb:author><sb:author><ce:surname>Schooley</ce:surname><ce:given-name>R.T.</ce:given-name></sb:author><sb:author><ce:surname>Rota</ce:surname><ce:given-name>T.R.</ce:given-name></sb:author><sb:author><ce:surname>Kennedy</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author><sb:author><ce:surname>Chanh</ce:surname><ce:given-name>T.C.</ce:given-name></sb:author><sb:author><ce:surname>Sato</ce:surname><ce:given-name>V.L.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>61</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>2024</sb:first-page><sb:last-page>2028</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>Klasse, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Klasse</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:author><ce:surname>Pipkorn</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Blomberg</ce:surname><ce:given-name>J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. nat. Acad. Sci. (Wash.)</sb:maintitle></sb:title><sb:volume-nr>85</sb:volume-nr></sb:series></sb:book-series><sb:date>1988</sb:date></sb:edited-book><sb:pages><sb:first-page>5225</sb:first-page><sb:last-page>5229</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>Lange, et al, 1989</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lange</ce:surname><ce:given-name>J.M.A.</ce:given-name></sb:author><sb:author><ce:surname>Vahlne</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Dekker</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>de Wolf</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Goudsmit</ce:surname><ce:given-name>J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibodies to an HIV-1 synthetic peptide with partial homology to MULV p15E do not protect against AIDS</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>402</sb:first-page><sb:last-page>403</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>Matsushita, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Matsushita</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Robert-Guroff</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Rusche</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Koito</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Hattori</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:author><ce:surname>Hoshino</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Javaherian</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Takatsuki</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Putney</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>62</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>2107</sb:first-page><sb:last-page>2114</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>Matthews, et al, 1986</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Matthews</ce:surname><ce:given-name>T.J.</ce:given-name></sb:author><sb:author><ce:surname>Langlois</ce:surname><ce:given-name>A.J.</ce:given-name></sb:author><sb:author><ce:surname>Robey</ce:surname><ce:given-name>W.G.</ce:given-name></sb:author><sb:author><ce:surname>Chang</ce:surname><ce:given-name>N.T.</ce:given-name></sb:author><sb:author><ce:surname>Gallo</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author><sb:author><ce:surname>Fischinger</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:author><ce:surname>Bolognesi</ce:surname><ce:given-name>D.P.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. nat. Acad. Sci. (Wash.)</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series></sb:book-series><sb:date>1986</sb:date></sb:edited-book><sb:pages><sb:first-page>9709</sb:first-page><sb:last-page>9713</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>Modrow, et al, 1987</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Modrow</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Hahn</ce:surname><ce:given-name>B.H.</ce:given-name></sb:author><sb:author><ce:surname>Shaw</ce:surname><ce:given-name>G.M.</ce:given-name></sb:author><sb:author><ce:surname>Gallo</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author><sb:author><ce:surname>Wong-Staal</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Wolf</ce:surname><ce:given-name>H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>61</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>570</sb:first-page><sb:last-page>578</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>Nara, et al, 1987</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nara</ce:surname><ce:given-name>P.L.</ce:given-name></sb:author><sb:author><ce:surname>Hatch</ce:surname><ce:given-name>W.C.</ce:given-name></sb:author><sb:author><ce:surname>Dunlop</ce:surname><ce:given-name>N.M.</ce:given-name></sb:author><sb:author><ce:surname>Robey</ce:surname><ce:given-name>W.G.</ce:given-name></sb:author><sb:author><ce:surname>Fischinger</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Simple, rapid, quantitative micro-syncytium forming assay for the detection of neutralizing antibody against infectious HTLV-III/LAV</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS Res. Hum. Retrovirus</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>283</sb:first-page><sb:last-page>302</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>Qureshi, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Qureshi</ce:surname><ce:given-name>N.M.</ce:given-name></sb:author><sb:author><ce:surname>Coy</ce:surname><ce:given-name>D.H.</ce:given-name></sb:author><sb:author><ce:surname>Garry</ce:surname><ce:given-name>R.F.</ce:given-name></sb:author><sb:author><ce:surname>Henderson</ce:surname><ce:given-name>L.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>553</sb:first-page><sb:last-page>558</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>Reitz, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Reitz</ce:surname><ce:given-name>M.S.</ce:given-name></sb:author><sb:author><ce:surname>Wilson</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Naugle</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Gallo</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author><sb:author><ce:surname>Robert-Guroff</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Generation of a neutralizing-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>57</sb:first-page><sb:last-page>63</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>Robert-Guroff, et al, 1985</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Robert-Guroff</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Brown</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Gallo</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature (Lond.)</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>72</sb:first-page><sb:last-page>74</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>Robertson, et al, 1988</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Robertson</ce:surname><ce:given-name>G.A.</ce:given-name></sb:author><sb:author><ce:surname>Kostek</ce:surname><ce:given-name>B.M.</ce:given-name></sb:author><sb:author><ce:surname>Schleif</ce:surname><ce:given-name>W.A.</ce:given-name></sb:author><sb:author><ce:surname>Lewis</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:author><ce:surname>Emini</ce:surname><ce:given-name>E.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. virol. Methods</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>195</sb:first-page><sb:last-page>202</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>Robinson, et al, 1989</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Robinson</ce:surname><ce:given-name>W.E.</ce:given-name></sb:author><sb:author><ce:surname>Montefiori</ce:surname><ce:given-name>D.C.</ce:given-name></sb:author><sb:author><ce:surname>Gillespie</ce:surname><ce:given-name>D.H.</ce:given-name></sb:author><sb:author><ce:surname>Mitchell</ce:surname><ce:given-name>W.M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Complement-mediated, antibody-dependent enhancement of HIV-1 infection <ce:italic>in vitro</ce:italic> is characterized by increased protein and RNA syntheses and infectious virus release</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. AIDS</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>33</sb:first-page><sb:last-page>42</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>Robinson, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Robinson</ce:surname><ce:given-name>W.E.</ce:given-name></sb:author><sb:author><ce:surname>Kawamura</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:author><ce:surname>Lake</ce:surname><ce:given-name>D.</ce:given-name></sb:author><sb:author><ce:surname>Masuho</ce:surname><ce:given-name>Y.</ce:given-name></sb:author><sb:author><ce:surname>Mitchell</ce:surname><ce:given-name>W.M.</ce:given-name></sb:author><sb:author><ce:surname>Hersh</ce:surname><ce:given-name>E.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection <ce:italic>in vitro</ce:italic></sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>64</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>5301</sb:first-page><sb:last-page>5305</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>Ruegg, et al, 1989</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ruegg</ce:surname><ce:given-name>C.L.</ce:given-name></sb:author><sb:author><ce:surname>Monell</ce:surname><ce:given-name>C.R.</ce:given-name></sb:author><sb:author><ce:surname>Strand</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>63</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>3257</sb:first-page><sb:last-page>3260</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>Scott, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Scott</ce:surname><ce:given-name>C.F.</ce:given-name><ce:suffix>Jr.</ce:suffix></sb:author><sb:author><ce:surname>Siver</ce:surname><ce:given-name>S.</ce:given-name></sb:author><sb:author><ce:surname>Profy</ce:surname><ce:given-name>A.T.</ce:given-name></sb:author><sb:author><ce:surname>Putney</ce:surname><ce:given-name>S.D.</ce:given-name></sb:author><sb:author><ce:surname>Langlois</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Weinhold</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Robinson</ce:surname><ce:given-name>J.E.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type III MN strain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. nat. Acad. Sci. (Wash.)</sb:maintitle></sb:title><sb:volume-nr>87</sb:volume-nr></sb:series></sb:book-series><sb:date>1990</sb:date></sb:edited-book><sb:pages><sb:first-page>8597</sb:first-page><sb:last-page>8601</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>Shafferman, et al, 1991</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Shafferman</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Jahrling</ce:surname><ce:given-name>P.B.</ce:given-name></sb:author><sb:author><ce:surname>Benveniste</ce:surname><ce:given-name>R.E.</ce:given-name></sb:author><sb:author><ce:surname>Lewis</ce:surname><ce:given-name>M.G.</ce:given-name></sb:author><sb:author><ce:surname>Phipps</ce:surname><ce:given-name>T.J.</ce:given-name></sb:author><sb:author><ce:surname>Eden-McCutchan</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:author><ce:surname>Sadoff</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Eddy</ce:surname><ce:given-name>G.A.</ce:given-name></sb:author><sb:author><ce:surname>Burke</ce:surname><ce:given-name>D.S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. nat. Acad. Sci. (Wash.)</sb:maintitle></sb:title><sb:volume-nr>88</sb:volume-nr></sb:series></sb:book-series><sb:date>1991</sb:date></sb:edited-book><sb:pages><sb:first-page>7126</sb:first-page><sb:last-page>7130</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>Skinner, et al, 1988a</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Skinner</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:author><ce:surname>Ting</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Langlois</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Weinhold</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Lyerly</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Javaherian</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Matthews</ce:surname><ce:given-name>T.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS Res. Hum. Retroviruses</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>187</sb:first-page><sb:last-page>197</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>Skinner, et al, 1988b</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Skinner</ce:surname><ce:given-name>M.A.</ce:given-name></sb:author><sb:author><ce:surname>Langlois</ce:surname><ce:given-name>A.J.</ce:given-name></sb:author><sb:author><ce:surname>McDanal</ce:surname><ce:given-name>C.B.</ce:given-name></sb:author><sb:author><ce:surname>McDougal</ce:surname><ce:given-name>J.S.</ce:given-name></sb:author><sb:author><ce:surname>Bolognesi</ce:surname><ce:given-name>D.P.</ce:given-name></sb:author><sb:author><ce:surname>Matthews</ce:surname><ce:given-name>T.J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>62</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>4195</sb:first-page><sb:last-page>4200</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>Trabaud, et al, 1989</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Trabaud</ce:surname><ce:given-name>M.-A.</ce:given-name></sb:author><sb:author><ce:surname>Lery</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:author><ce:surname>Desgranges</ce:surname><ce:given-name>C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Human monoclonal antibodies with a protective activity against tetanus toxin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta path. microbiol. immunol. Scand.</sb:maintitle></sb:title><sb:volume-nr>97</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>671</sb:first-page><sb:last-page>676</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>Weiss, et al, 1985</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Weiss</ce:surname><ce:given-name>R.A.</ce:given-name></sb:author><sb:author><ce:surname>Clapham</ce:surname><ce:given-name>P.R.</ce:given-name></sb:author><sb:author><ce:surname>Cheingsong-Popov</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:author><ce:surname>Dalgleish</ce:surname><ce:given-name>A.G.</ce:given-name></sb:author><sb:author><ce:surname>Carne</ce:surname><ce:given-name>C.A.</ce:given-name></sb:author><sb:author><ce:surname>Weller</ce:surname><ce:given-name>I.V.D.</ce:given-name></sb:author><sb:author><ce:surname>Tedder</ce:surname><ce:given-name>R.S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature (Lond.)</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>69</sb:first-page><sb:last-page>72</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>Wilson, et al, 1990</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Wilson</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>Reitz</ce:surname><ce:given-name>M.</ce:given-name><ce:suffix>Jr.</ce:suffix></sb:author><sb:author><ce:surname>Aldrich</ce:surname><ce:given-name>K.</ce:given-name></sb:author><sb:author><ce:surname>Klasse</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:author><ce:surname>Blomberg</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:author><ce:surname>Gallo</ce:surname><ce:given-name>R.C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>64</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>3240</sb:first-page><sb:last-page>3248</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1</title></titleInfo><titleInfo type="translated" lang="fr"><title>Anticorps monoclonaux humain et murin dirigés contre une séquence conservée de la gp41 (aa583-599) du virus de l'immunodéficience humaine</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Ebersold</namePart><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><affiliation>Corresponding author.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Boyer</namePart><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.J.</namePart><namePart type="family">Klasse</namePart><affiliation>Section of Virology, Lund University, Lund (Sweden)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Holnigue</namePart><affiliation>Centre Régional de Transfusion sanguine, 59000 Lille (France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Fraisier</namePart><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Cocchi</namePart><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Pipkorn</namePart><affiliation>Novabiochem AG, Sandhausen, Heidelberg (Germany)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Blomberg</namePart><affiliation>Section of Virology, Lund University, Lund (Sweden)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Desgranges</namePart><affiliation>Unité de Recherche sur les Hépatites, le SIDA et les Rétrovirus humains, INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03 (France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Summary: Human spleen cells from an HIV-seropositive donor were immunized in vitro with the aa583–599 peptide conjugated to an heptalysyl core. This sequence was derived from the putatively HIV-immunosuppressive region of HIV1 gp41. The same conjugated peptide was used to immunize mice. One human and one mouse IgM monoclonal antibody (mAb) directed against the aa583–599 peptide were obtained. The two mAb had distinct patterns of reactivity against a panel of 42 peptides with modified sequences. Neither of the mAb inhibited the immunosuppressive effect of aa583–599 octopus-lysconjugated peptide on anti-CD3 Ab-induced lymphoproliferation. In addition, both mAb did not neutralize cell-free virus transmission or enhance HIV infection. However, HmAb inhibited formation of syncytia between HIV1-infected (but not HIV2-infected cells) and non-infected target cells at concentrations above 20 μg/ml, whereas MmAb did not have any effect. The degree of conservation of the aa583–599 region makes HmAb a candidate for use as a group-specific reagent in future HIV1 passive immunotherapy protocols.</abstract><abstract lang="fr">Les lymphocytes de la rate d'un donneur séropositif pour le VIH ont été immunisés in vitro par un peptide synthétique constitué des acides aminés 583 à 599 de la région immunosuppressive de la gp41 du VIH. Pour l'immunisation, le peptide a été couplé à un «noyau heptalysine portant huit extrémités NH2-réactives. Ce même peptide a été injecté en parallèle à des souris. Un anticorps monoclonal humain et un anticorps monoclonal murin ont été obtenus. Tous deux d'isotype IgM, ils présentent une réactivité différente sur un groupe de 42 peptides présentant des modifications de séquence. Les deux anticorps n'inhibent pas les propriétés immunosuppressives du peptide 583–599 et ne neutralisent ni n'augmentent l'infection par du virus libre. Toutefois, l'anticorps monoclonal humain, et lui seul, présente la capacité d'inhiber la formation de syncytia entre des cellules infectées par différentes souches du VIH1 et des cellules cibles, cela à une concentration de 20 μg/ml. Le haut degré de conservation des acides aminés dans la région 583–599 fait de l'anticorps monoclonal humain un candidat éventuel pour des études d'immunothérapie passive.</abstract><subject lang="en"><genre>Key-words</genre><topic>Lymphocyte, Peptide, HIV, AIDS, mAb, IgM, Immunotherapy</topic><topic>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</topic></subject><subject lang="fr"><genre>Mots-clés</genre><topic>Lymphocyte, HIV, Peptide, Anticorps monoclonal, IgM, VIH1, SIDA, Immunothérapie</topic><topic>gp41, Immunosuppression, Syncytia, pHIVIS, Heptalysine</topic></subject><relatedItem type="host"><titleInfo><title>Research in Virology</title></titleInfo><titleInfo type="abbreviated"><title>X135</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued></originInfo><identifier type="ISSN">0923-2516</identifier><identifier type="PII">S0923-2516(06)X8065-2</identifier><part><date>1992</date><detail type="volume"><number>143</number><caption>vol.</caption></detail><detail type="supplement"><number>C</number><caption>Suppl.</caption></detail><extent unit="issue-pages"><start>A3</start><end>A14</end></extent><extent unit="issue-pages"><start>5</start><end>434</end></extent><extent unit="pages"><start>179</start><end>191</end></extent></part></relatedItem><identifier type="istex">D485D531AA1B2F6D22431C4A22EFCE818A012DEF</identifier><identifier type="ark">ark:/67375/6H6-03DRLF6T-T</identifier><identifier type="DOI">10.1016/S0923-2516(06)80102-0</identifier><identifier type="PII">S0923-2516(06)80102-0</identifier><identifier type="ArticleID">80102</identifier><accessCondition type="use and reproduction" contentType="copyright">©1992 Éditions Scientifiques Elsevier, Paris</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Éditions Scientifiques Elsevier, Paris, ©1992</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-03DRLF6T-T/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D485D531AA1B2F6D22431C4A22EFCE818A012DEF
|texte= Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1
}}
| This area was generated with Dilib version V0.6.33. |  |